J&J invests in Clarimedix nitric oxide therapy; Eisai and Nobelpharma launch water-soluble prodrug seizure treatment;

> Clarimedix has nailed down an undisclosed investment from Johnson & Johnson ($JNJ) to fund a proof-of-concept study for its nitric oxide donor therapy, which triggers NO production through a light emitting diode patch applied over the skin. Release

> DSM, a biomedical material sciences company, has joined the European Union-funded PANOPTES consortium to help develop tailored amino acid-based polymers toward sustained drug delivery for the posterior segment of the eye. Story

> Eisai and Nobelpharma Co. are launching in Japan a water-soluble prodrug version of phenytoin injection, a long-used epilepsy and anti-seizure treatment. This version is intended to reduce skin irritation during intravenous infusion and to be easier for the patient to handle. Release

> Shire has signed a deal with Prasco Laboratories allowing Prasco to distribute a generic version of its Carbatrol extended-release capsules, which are indicated to treat certain types of seizures and nerve pain. Article

> Engineered BioPharmaceuticals is profiled on its efforts to develop dry-powdered versions of drugs that can be delivered in inhalers, nasal devices or syringes. Report

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.